Here five things to know:
1. The Rejuve treatment is a minimally invasive treatment for degenerative disc disease and low back pain.
2. Intralink-Spine tested the safety and feasibility of its product in Malaysia.
3. Two of the four patients who have been involved in the study for six-months reported no pain or disability, while a third patient has only mild pain and zero disability.
4. The safety study’s success has paved the way for a multi-site pivotal study in Southeast Asia.
5. Company CEO Lyle Hawkins explained, “About 80 percent of the adults in the U.S. experience significant back pain at some point in their life,” and the Rejuve study data makes him optimistic about the product’s potential to treat low back pain.
More articles on devices:
Zimmer Biomet enjoys a 106% increase in 2016 earnings — 8 things to know
5 key points on Trump’s meeting with pharma execs
FDA premarket approvals dropped 51% in 2016 — but 2017 shaping up differently: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
